Frits H.A.F. de Man

Impact of a comprehensive cardiac rehabilitation programme versus coronary revascularisation in patients with stable angina pectoris: study protocol for the PRO-FIT randomised controlled trial

J. Geleijnse, E. Adang, R. V. van Geuns, 2023, BMC Cardiovascular Disorders.

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2014, The Lancet.

Incidence of periprocedural myocardial infarction following stent implantation: Comparison between first‐ and second‐generation drug‐eluting stents

M. Stoel, C. von Birgelen, G. Linssen, 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Three‐year clinical outcome after treatment of chronic total occlusions with second‐generation drug‐eluting stents in the TWENTE trial

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Reproducibility of volumetric intravascular ultrasound radiofrequency-based analysis of coronary plaque composition in vivo

M. Stoel, C. von Birgelen, F. de Man, 2008, The International Journal of Cardiovascular Imaging.

Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS Trials.

Maarten J. IJzerman, J. W. Louwerenburg, A. Maas, 2016, JACC. Cardiovascular interventions.

High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.

J. W. Louwerenburg, M. Stoel, I. Knottnerus, 2018, International journal of cardiology.

Long‐Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer‐Generation Drug‐Eluting Stents

M. Stoel, C. von Birgelen, G. Linssen, 2018, Journal of the American Heart Association.

Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.

C. von Birgelen, G. Linssen, C. Schotborgh, 2019, JAMA cardiology.

Normal Oxidative Stress and Enhanced Lipoprotein Resistance to In Vitro Oxidation in Hypertriglyceridemia: Effects of Bezafibrate Therapy

A. Van der Laarse, E. Schwedhelm, F. de Man, 2000, Arteriosclerosis, thrombosis, and vascular biology.

5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2018, JACC. Cardiovascular interventions.

In vitro lipolysis of human VLDL: effect of different VLDL compositions in normolipidemia, familial combined hyperlipidemia and familial hypertriglyceridemia.

T. D. de Bruin, F. de Man, H. van Barlingen, 1996, Atherosclerosis.